Inactivation of the FHIT gene favors bladder cancer development

Clinical Cancer Research

Volumn 10, Issue 22, 2004, Pages 7607-7612

  Vecchione, Andrea ^a,b   Sevignani, Cinzia ^a   Giarnieri, Enrico ^a,b   Zanesi, Nicola ^a   Ishii, Hideshi ^a,c   Cesari, Rossano ^a   Fong, Louise Y Y ^a   Gomella, Leonard G ^a   Croce, Carlo M ^a   Baffa, Raffaele ^a,d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; FHIT GENE; FLOW CYTOMETRY; GENE; GENE INACTIVATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA;

ACID ANHYDRIDE HYDROLASES; ADENOVIRIDAE; ANIMALS; BUTYLHYDROXYBUTYLNITROSAMINE; CARCINOMA, TRANSITIONAL CELL; CELL LINE; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; GENE THERAPY; GENOTYPE; HETEROZYGOTE; HUMANS; IMMUNOBLOTTING; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 9344255479     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0341     Document Type: Article

References (20)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer Statistics 2004. CA - Cancer J Clin 2004;54:8-29.
2. Gomella LG, Mastrangelo MJ, Mc Cue PA, et al. Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol 2001;166:1291-5.
3. Kuball J, Wen SF, Leissner J, et al. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol 2002;20:957-65.
4. Ohta M, Inoue H, Cotticelli MG, et al. The FHIT gene spanning the chromosome 3p14.2 fragile site, and renal carcinoma-associated t(3; 8) breakpoint, is abnormal in digestive tract cancers. Cell 1996;84:587-97.
5. Vieten L, Belair CD, Savelieva L, et al. Minimal deletion of 3p13-14.2 associated with immortalization of human uroepithelial cells. Genes Chromosomes Cancer 1998;21:39-48.
6. Ishii H, Dumon KR, Vecchione A, et al. Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. Cancer Res 2001;61:1578-84.
7. Roz L, Gramegna M, Ishii H, Croce CM, Sozzi G. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc Natl Acad Sci USA 2002;99:3615-20.
8. Dumon KR, Ishii H, Vecchione A, et al. Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res 2001;61:4827-36.
9. Ishii H, Dumon KR, Vecchione A, et al. Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies. J Am Med Assoc 2001;286:2441-9.
10. Tamano S, Hagiwara A, Suzuki E, et al. Time- and dose-dependent induction of invasive urinary bladder cancers by N-ethyl-N-(4-hydroxybutyl)nitrosamine in B6C3F1 mice. Jpn J Cancer Res 1991;82:650-6.
11. Ota T, Asamoto M, Toriyama-Baba H, et al. Transgenic rats carrying copies of the human c-Ha-ras proto-oncogene exhibit enhanced susceptibility to N-butyl-N-(4-hydroxybutyl)nitrosamine bladder carcinogenesis. Carcinogenesis (Lond) 2000;21:1391-6.
12. Fong LY, Fidanza V, Zanesi N, et al. Muir-Torre-like syndrome in Fhit-deficient mice. Proc Natl Acad Sci USA 2000;97:4742-7.
13. Vecchione A, Ishii H, Baldassarre G, et al. FEZ1/LZTS1 is down regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma (TCC) cells. Am J Path 2002;160:1345-52.
14. Bertram JS, Craig AW. Specific induction of bladder cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response. Eur J Cancer 1972;8:587-94.
15. Jones RF, Debiec-Rychter M, Wang CY. Chemical Carcinogenesis of the urinary bladder-a status report. J Cancer Res Clin Oncol 1992;118:411-19.
16. Fong LY, Fidanza V, Zanesi N, et al. Muir-Torre-like syndrome in Fhit-deficient mice. Proc Natl Acad Sci USA 2000;97:4742-7.
17. Muraoka RS, Lenferink AE, Law B, et al. ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol Cell Biol 2002;22:2204-19.
18. Zanesi N, Fidanza V, Fong LY, et al. The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci USA 2001;98:10250-5.
19. Baffa R, Gomella LG, Vecchione A, et al. Loss of FHIT expression in transitional cell carcinoma of the urinary bladder. Am J Path 2000;156:419-24.
20. Sevignani C, Calin GA, Cesari R, et al. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in breast cancer cell lines. Cancer Res 2003;63:1183-7.